DOVATO Drug Patent Profile
✉ Email this page to a colleague
When do Dovato patents expire, and what generic alternatives are available?
Dovato is a drug marketed by Viiv Hlthcare and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and eighty patent family members in forty-nine countries.
The generic ingredient in DOVATO is dolutegravir sodium; lamivudine. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dolutegravir sodium; lamivudine profile page.
DrugPatentWatch® Generic Entry Outlook for Dovato
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 24, 2031. This may change due to patent challenges or generic licensing.
There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for DOVATO
International Patents: | 280 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 45 |
Clinical Trials: | 7 |
Patent Applications: | 49 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for DOVATO |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DOVATO |
What excipients (inactive ingredients) are in DOVATO? | DOVATO excipients list |
DailyMed Link: | DOVATO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for DOVATO
Generic Entry Date for DOVATO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for DOVATO
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
ViiV Healthcare | Phase 1 |
Saint Michael's Medical Center | Phase 4 |
Societa' Italiana Di Malattie Infettive E Tropicali | Phase 3 |
Pharmacology for DOVATO
Anatomical Therapeutic Chemical (ATC) Classes for DOVATO
Paragraph IV (Patent) Challenges for DOVATO
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
DOVATO | Tablets | dolutegravir sodium; lamivudine | 50 mg/300 mg | 211994 | 1 | 2019-07-30 |
US Patents and Regulatory Information for DOVATO
DOVATO is protected by three US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of DOVATO is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting DOVATO
Antiviral therapy
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HIV INFECTION
Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viiv Hlthcare | DOVATO | dolutegravir sodium; lamivudine | TABLET;ORAL | 211994-001 | Apr 8, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Viiv Hlthcare | DOVATO | dolutegravir sodium; lamivudine | TABLET;ORAL | 211994-001 | Apr 8, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Viiv Hlthcare | DOVATO | dolutegravir sodium; lamivudine | TABLET;ORAL | 211994-001 | Apr 8, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for DOVATO
When does loss-of-exclusivity occur for DOVATO?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
African Regional IP Organization (ARIPO)
Patent: 51
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 11209788
Estimated Expiration: ⤷ Sign Up
Patent: 14202404
Estimated Expiration: ⤷ Sign Up
Patent: 14202405
Estimated Expiration: ⤷ Sign Up
Patent: 14202406
Estimated Expiration: ⤷ Sign Up
Patent: 16204987
Estimated Expiration: ⤷ Sign Up
Patent: 17268621
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2012018670
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 87691
Estimated Expiration: ⤷ Sign Up
Patent: 67453
Estimated Expiration: ⤷ Sign Up
Patent: 03988
Estimated Expiration: ⤷ Sign Up
Patent: 60290
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 12002080
Estimated Expiration: ⤷ Sign Up
China
Patent: 2791129
Estimated Expiration: ⤷ Sign Up
Patent: 5311033
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 02152
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 120423
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0150770
Estimated Expiration: ⤷ Sign Up
Patent: 0180855
Estimated Expiration: ⤷ Sign Up
Patent: 0181531
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 16509
Estimated Expiration: ⤷ Sign Up
Patent: 20457
Estimated Expiration: ⤷ Sign Up
Patent: 21040
Estimated Expiration: ⤷ Sign Up
Patent: 18029
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 31027
Estimated Expiration: ⤷ Sign Up
Patent: 32970
Estimated Expiration: ⤷ Sign Up
Patent: 27542
Estimated Expiration: ⤷ Sign Up
Patent: 94972
Estimated Expiration: ⤷ Sign Up
Dominican Republic
Patent: 012000205
Estimated Expiration: ⤷ Sign Up
Patent: 021000147
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 12012106
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 5176
Estimated Expiration: ⤷ Sign Up
Patent: 2868
Estimated Expiration: ⤷ Sign Up
Patent: 7601
Estimated Expiration: ⤷ Sign Up
Patent: 1290583
Estimated Expiration: ⤷ Sign Up
Patent: 1690872
Estimated Expiration: ⤷ Sign Up
Patent: 1892277
Estimated Expiration: ⤷ Sign Up
Patent: 2190473
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 31027
Estimated Expiration: ⤷ Sign Up
Patent: 32970
Estimated Expiration: ⤷ Sign Up
Patent: 27542
Estimated Expiration: ⤷ Sign Up
Patent: 51249
Estimated Expiration: ⤷ Sign Up
Patent: 94972
Estimated Expiration: ⤷ Sign Up
Patent: 16599
Estimated Expiration: ⤷ Sign Up
Finland
Patent: 94972
Estimated Expiration: ⤷ Sign Up
France
Patent: C1043
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 79522
Estimated Expiration: ⤷ Sign Up
Patent: 09629
Estimated Expiration: ⤷ Sign Up
Patent: 50335
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 26849
Estimated Expiration: ⤷ Sign Up
Patent: 37812
Estimated Expiration: ⤷ Sign Up
Patent: 40554
Estimated Expiration: ⤷ Sign Up
Patent: 800042
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 1007
Estimated Expiration: ⤷ Sign Up
Patent: 5182
Estimated Expiration: ⤷ Sign Up
Patent: 7267
Estimated Expiration: ⤷ Sign Up
Patent: 7658
Estimated Expiration: ⤷ Sign Up
Patent: 1959
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 68386
Estimated Expiration: ⤷ Sign Up
Patent: 13518107
Estimated Expiration: ⤷ Sign Up
Patent: 16145204
Estimated Expiration: ⤷ Sign Up
Patent: 17008087
Estimated Expiration: ⤷ Sign Up
Patent: 18127473
Estimated Expiration: ⤷ Sign Up
Patent: 19167371
Estimated Expiration: ⤷ Sign Up
Patent: 21091705
Estimated Expiration: ⤷ Sign Up
Patent: 22071126
Estimated Expiration: ⤷ Sign Up
Patent: 23085431
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 932970
Estimated Expiration: ⤷ Sign Up
Patent: 2018013
Estimated Expiration: ⤷ Sign Up
Patent: 32970
Estimated Expiration: ⤷ Sign Up
Patent: 27542
Estimated Expiration: ⤷ Sign Up
Patent: 94972
Estimated Expiration: ⤷ Sign Up
Luxembourg
Patent: 0090
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 8334
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 6891
Estimated Expiration: ⤷ Sign Up
Patent: 7937
Estimated Expiration: ⤷ Sign Up
Patent: 7938
Estimated Expiration: ⤷ Sign Up
Patent: 12008774
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 182
Estimated Expiration: ⤷ Sign Up
Patent: 058
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 002
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 1319
Estimated Expiration: ⤷ Sign Up
Patent: 7824
Estimated Expiration: ⤷ Sign Up
Patent: 7826
Estimated Expiration: ⤷ Sign Up
Patent: 7827
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 18036
Estimated Expiration: ⤷ Sign Up
Patent: 32970
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 121524
Estimated Expiration: ⤷ Sign Up
Patent: 160180
Estimated Expiration: ⤷ Sign Up
Philippines
Patent: 016500195
Estimated Expiration: ⤷ Sign Up
Patent: 018502489
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 31027
Estimated Expiration: ⤷ Sign Up
Patent: 32970
Estimated Expiration: ⤷ Sign Up
Patent: 27542
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 31027
Estimated Expiration: ⤷ Sign Up
Patent: 32970
Estimated Expiration: ⤷ Sign Up
Patent: 27542
Estimated Expiration: ⤷ Sign Up
Patent: 94972
Estimated Expiration: ⤷ Sign Up
San Marino
Patent: 01500177
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 123
Estimated Expiration: ⤷ Sign Up
Patent: 323
Estimated Expiration: ⤷ Sign Up
Patent: 728
Estimated Expiration: ⤷ Sign Up
Patent: 183
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 2614
Estimated Expiration: ⤷ Sign Up
Patent: 201509476R
Estimated Expiration: ⤷ Sign Up
Patent: 201707183T
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 31027
Estimated Expiration: ⤷ Sign Up
Patent: 32970
Estimated Expiration: ⤷ Sign Up
Patent: 27542
Estimated Expiration: ⤷ Sign Up
Patent: 94972
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1205586
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1830715
Estimated Expiration: ⤷ Sign Up
Patent: 1883750
Estimated Expiration: ⤷ Sign Up
Patent: 1964923
Estimated Expiration: ⤷ Sign Up
Patent: 120128640
Estimated Expiration: ⤷ Sign Up
Patent: 160111536
Estimated Expiration: ⤷ Sign Up
Patent: 170078868
Estimated Expiration: ⤷ Sign Up
Patent: 180078358
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 43066
Estimated Expiration: ⤷ Sign Up
Patent: 70811
Estimated Expiration: ⤷ Sign Up
Patent: 88925
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 12000376
Estimated Expiration: ⤷ Sign Up
Turkey
Patent: 1807704
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 5556
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering DOVATO around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20080009733 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | ⤷ Sign Up |
South Korea | 101847887 | ⤷ Sign Up | |
Cyprus | 1120345 | ⤷ Sign Up | |
Slovenia | 3127542 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DOVATO
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2932970 | PA2018013 | Lithuania | ⤷ Sign Up | PRODUCT NAME: DERINYS, APIMANTIS DOLUTEGRAVIRA ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA (PVZ., DOLUTEGRAVIRO NATRI) IR RILPIVIRINA ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA (PVZ., RILPIVIRINO HIDROCHLORIDA); REGISTRATION NO/DATE: EU/1/18/1282/001-002 20180516 |
1874117 | CR 2014 00032 | Denmark | ⤷ Sign Up | PRODUCT NAME: DOLUTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892/001-002 20140121 |
2465580 | 2190020-4 | Sweden | ⤷ Sign Up | PRODUCT NAME: CABOTEGRAVIR OR A PHAMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/20/1481 20201221 |
1874117 | 1490036-9 | Sweden | ⤷ Sign Up | PRODUCT NAME: DOLUTEGRAVIR ELLER ETT FARMACEUTISKT ACCEPTABELT SALT ELLER SOLVAT DAERAV, INKLUSIVE DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892 20140116 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |